Announcements Trials

Browse Landscape

Phase

Status

Unknown 9 Recruiting 6 Completed 6 Withdrawn 1 Terminated 1 Suspended 1 Not yet recruiting 1 Active not recruiting 1

Sponsor Class

OTHER 166 INDUSTRY 96 NETWORK 14 NIH 8 OTHER_GOV 1 FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lung Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Gemcitabine 4 Cisplatin 4 Rituximab 2 Fluorouracil 2 Everolimus 2 tislelizumab 1 phosphorylethanolamine 1 parsaclisib 1 human papillomavirus vaccine, L1 type 16, 18 1 famitinib 1 dalpiciclib 1 Zinc Sulfate 1 Zinc 1 Vitamin B 6 1 Tamoxifen 1 Sunitinib 1 Sorafenib 1 Radiotherapy, Adjuvant 1 Pyridoxine 1 Proton Pump Inhibitors 1 Prednisone 1 Platelet Transfusion 1 Photochemotherapy 1 Pemetrexed 1 Patient Portals 1 Paclitaxel 1 Oxaliplatin 1 Neoadjuvant Therapy 1 N-hydroxy-4-acetylaminostilbene 1 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × OTHER_GOV × Docetaxel × Clear all

NCT01356368 2014-01-22

Customizing

National Guard Health Affairs

Phase 2 Terminated

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡